Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 8 | 2017 | 94 | 3.000 |
Why?
|
| Income | 3 | 2017 | 80 | 1.560 |
Why?
|
| Insurance Coverage | 2 | 2017 | 15 | 1.080 |
Why?
|
| Oligodendroglioma | 2 | 2016 | 6 | 1.060 |
Why?
|
| Astrocytoma | 2 | 2016 | 18 | 1.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 172 | 1.020 |
Why?
|
| Medically Uninsured | 2 | 2017 | 13 | 0.700 |
Why?
|
| Radiation Injuries | 3 | 2017 | 29 | 0.670 |
Why?
|
| Glioma | 3 | 2014 | 24 | 0.640 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 22 | 0.580 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2017 | 4 | 0.570 |
Why?
|
| Gliosarcoma | 1 | 2017 | 2 | 0.560 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 17 | 0.560 |
Why?
|
| Cranial Irradiation | 2 | 2014 | 11 | 0.540 |
Why?
|
| Insurance, Health | 1 | 2016 | 21 | 0.530 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2018 | 52 | 0.520 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 86 | 0.500 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 305 | 0.490 |
Why?
|
| Ependymoma | 1 | 2015 | 17 | 0.480 |
Why?
|
| Sleep Apnea, Central | 1 | 2015 | 30 | 0.480 |
Why?
|
| Young Adult | 6 | 2018 | 2022 | 0.460 |
Why?
|
| Adolescent | 5 | 2018 | 2177 | 0.450 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4830 | 0.420 |
Why?
|
| Aged | 9 | 2019 | 9076 | 0.400 |
Why?
|
| Middle Aged | 9 | 2018 | 9016 | 0.400 |
Why?
|
| Male | 13 | 2019 | 14810 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 177 | 0.380 |
Why?
|
| Adult | 8 | 2018 | 7901 | 0.360 |
Why?
|
| Female | 10 | 2019 | 15250 | 0.330 |
Why?
|
| Humans | 14 | 2019 | 27134 | 0.300 |
Why?
|
| Medicaid | 2 | 2017 | 33 | 0.270 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 350 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 83 | 0.260 |
Why?
|
| Medicare | 2 | 2017 | 120 | 0.260 |
Why?
|
| Prognosis | 3 | 2019 | 804 | 0.250 |
Why?
|
| Regression Analysis | 2 | 2016 | 258 | 0.250 |
Why?
|
| Age Factors | 2 | 2016 | 775 | 0.220 |
Why?
|
| United States | 3 | 2019 | 2056 | 0.200 |
Why?
|
| Survival Rate | 2 | 2019 | 344 | 0.170 |
Why?
|
| Hippocampus | 2 | 2013 | 276 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2019 | 350 | 0.160 |
Why?
|
| Melanoma | 1 | 2019 | 58 | 0.150 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2019 | 65 | 0.150 |
Why?
|
| Propensity Score | 1 | 2018 | 36 | 0.150 |
Why?
|
| Private Sector | 1 | 2017 | 2 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 18 | 0.140 |
Why?
|
| Social Class | 1 | 2017 | 66 | 0.140 |
Why?
|
| Frail Elderly | 1 | 2017 | 50 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2017 | 261 | 0.130 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 3 | 0.130 |
Why?
|
| Paranasal Sinuses | 1 | 2017 | 63 | 0.130 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 100 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2013 | 36 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 331 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 164 | 0.120 |
Why?
|
| Standard of Care | 1 | 2014 | 13 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 55 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2014 | 33 | 0.110 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 13 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 52 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3542 | 0.100 |
Why?
|
| Limbic System | 1 | 2011 | 7 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 7 | 0.090 |
Why?
|
| Brain | 1 | 2017 | 1648 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 1104 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 13 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 368 | 0.040 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2017 | 3 | 0.040 |
Why?
|
| Facial Pain | 1 | 2017 | 7 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 38 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2017 | 39 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 2017 | 54 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 347 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 422 | 0.030 |
Why?
|
| Rhinitis | 1 | 2017 | 144 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 892 | 0.030 |
Why?
|
| Body Burden | 1 | 2013 | 7 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2013 | 12 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2011 | 216 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3528 | 0.010 |
Why?
|